“Full metal jacket” (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions

详细信息    查看全文

• 作者：Jiro Aoki ; Andrew T.L. Ong ; Gaston A. Rodriguez Granillo ; Eugè ; ne P. McFadden ; Carlos A.G. van Mieghem ; Marco Valgimigli ; Keiichi Tsuchida ; Georgios Sianos ; Evelyn Regar ; Peter P.T. de Jaegere ; Wi
• 关键词：Body mass index ; Enhanced external counterpulsation therapy ; Myocardial infarction
• 刊名：American Heart Journal
• 出版年：2005
• 出版时间：November 2005
• 年：2005
• 卷：150
• 期：5
• 页码：994-999
• 全文大小：139 K

文摘

To compare the effects of estrogen and estrogen plus progestin on levels of C-reactive protein (CRP) and interleukin-6 (IL-6), and to examine the relationship between these changes and progression of angiographically defined coronary disease.

Methods

Baseline and follow-up (year 1 and year 3) plasma levels of IL-6 and CRP were measured in a subset of 232 patients from the Estrogen Replacement in Atherosclerosis (ERA) trial.

Results

Serial angiograms were also available at baseline and closeout. Estrogen alone increased CRP by 40 % (P = .01) at 1 year and 38 % P = .002) at closeout. Estrogen plus medroxyprogesterone acetate increased CRP by 44.7 % P = .001) at 1 year and 54.7 % P = .0001) at closeout as compared with baseline levels. There were no significant changes in IL-6 with either treatment. In women in the active treatment arm, change in CRP during the first year was not associated with progression of coronary disease P = .2).

Conclusions

Estrogen and estrogen plus medroxyprogesterone significantly raise CRP levels in women with established coronary disease. In contrast, IL-6 levels are not affected by estrogen or estrogen plus progestin. Estrogen-induced changes in CRP are not associated with progression of atherosclerosis.